-
Start Preamble
By Notice dated February 5, 2003, and published in the Federal Register on February 12, 2003, (68 FR 7147), Cedarburg Pharmaceuticals, LLS 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic classes of controlled substances listed below:
Drug Schedule Tetrahydrocannabinols (7370) I Oxycodone (9143) II Hydromorphone (9150) II Hydrocodone (9193) II The firm plans to manufacture the listed controlled substances for distribution to its customers.
No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of Cedarburg Pharmaceuticals, LLC, to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Cedarburg Pharmaceuticals, LLC, to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted.
Start SignatureStart Printed Page 35916End Signature End PreambleDated: June 4, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 03-15197 Filed 6-16-03; 8:45 am]
BILLING CODE 4410-09-M
Document Information
- Published:
- 06/17/2003
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- 03-15197
- Pages:
- 35915-35916 (2 pages)
- PDF File:
- 03-15197.pdf